exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087909 RNA Name: hsa-miR-20b-5p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 134169850 End Site(bp): 134169872 External Links: hsa-miR-20b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RIT1 chr1 155897808 155911404 - CHD2 chr15 92900189 93027996 + ARMC8 chr3 138187248 138298384 + MAGI3 chr1 113390515 113685923 + RPUSD3 chr3 9837849 9844602 - KLF3 chr4 38664197 38701517 + CYLD chr16 50742050 50801935 + WASF3 chr13 26557683 26688948 + PLEKHM1 chr17 45435900 45490749 - ATXN1 chr6 16299112 16761491 - NSD2 chr4 1871393 1982207 + CHD9 chr16 53055033 53329150 + STRIP1 chr1 110031577 110074641 + FCF1 chr14 74713144 74738620 + SMYD3 chr1 245749342 246507312 - PXYLP1 chr3 141228726 141367753 + DNAJC27 chr2 24943636 24972094 - EEF2 chr19 3976056 3985463 - AMPD2 chr1 109616104 109632053 + LONP2 chr16 48244300 48363122 + C9orf40 chr9 74946583 74952912 - NAA16 chr13 41311267 41377030 + CRCP chr7 66114604 66154568 + CUL1 chr7 148697914 148801110 + MTHFR chr1 11785723 11806455 - PXDN chr2 1631887 1744852 - ZNF468 chr19 52838010 52857649 - EAPP chr14 34515938 34539711 - IKZF2 chr2 212999691 213152427 - SENP1 chr12 48042897 48106079 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000494 chr13 76134888 76143643 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC015871.3 chr15 79920195 79922455 - AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC024940.6 chr12 31280422 31280895 - AC084082.1 chr8 66112667 66126632 + AC087477.2 chr15 96354237 96405235 + AC243964.3 chr19 44631573 44725217 - AL031428.1 chr1 23020147 23088058 - AL137782.1 chr13 75549773 75807120 + AL158206.1 chr9 19453209 19455173 + AL161772.1 chr13 20699307 20703718 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - CKMT2-AS1 chr5 81201341 81301565 - EPB41L4A-AS1 chr5 112160526 112164818 + ERICD chr8 140636281 140638283 + FGD5-AS1 chr3 14920347 14948424 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - HOTAIR chr12 53962308 53974956 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.